What We're Reading: Page 159
Industry reads hand-picked by our editors
Jun 28, 2021
-
The Wall Street Journal
Johnson & Johnson Settles New York Opioid Case for $230 Million
-
The Atlantic
The mRNA Vaccines Are Extraordinary, but Novavax Is Even Better
-
FierceBiotech
AstraZeneca names Galbraith as Baselga successor in cancer R&D
-
Reuters
Idorsia to trial self-injection drug for heart attack victims
Jun 25, 2021
Jun 24, 2021
Jun 23, 2021
-
HuffPost
Can America Finally Do Something On Drug Prices? This Democratic Senator Thinks So.
-
Caixin Global
China Approves Its First CAR-T Cell Therapy
-
Evaluate Vantage
EQRX vows to slash drug prices where others have failed
-
STAT
Peter Bach, industry critic, joins company aiming to make liquid biopsies
Jun 22, 2021
-
The New York Times
New Alzheimer’s Drug Could Cost the Government as Much as It Spends on NASA
-
STAT
BIO's chief on the FDA commissioner rumors, drug pricing, and IP rights
-
Bloomberg
Amarin Rebuffed in High Court Bid to Revive Vascepa Patents
-
The Boston Globe
Pear Therapeutics to go public in $1.6 billion SPAC deal to treat diseases with software
Jun 21, 2021
-
FT
GSK faces struggle to convince investors as activist Elliott lurks
-
The Wall Street Journal
Moderna Plans to Expand Production to Make Covid-19 Vaccine Boosters, Supply More Countries
-
FierceBiotech
Roche's Alzheimer's drug lowers biomarkers of inherited disease
-
C&EN
Vaccines could make big Ebola outbreaks a thing of the past
Jun 18, 2021
-
Timmerman Report
On Juneteenth, Honoring 22 Black Biotech Leaders
-
The Washington Post
How Pfizer engineers overcame early obstacles to produce 3 billion shots
-
STAT
Athira Pharma CEO placed on leave amid claims of altered images
-
Reuters
CureVac may let contractors make rival vaccines if own shot fails - CEO
Previous
